Picture loading failed.

Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-464-1mg 1mg Inquiry
GMP-Bios-ab-464-10mg 10mg Inquiry
GMP-Bios-ab-464-100mg 100mg Inquiry
GMP-Bios-ab-464-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody
INN Name Radretumab
TargetFN extra domain B
Formatdi-scFv + CH4
Species ReactivityHuman
CH1 IsotypeIgE
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBrain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease
Development Techna